Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. - Test2 - elhamkhani - TriplyDB

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

http://www.wikidata.org/entity/Q37244781

about

Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Clinical use of Bevacizumab in treating refractory glaucoma Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization Differential distribution of blood and lymphatic vessels in the murine cornea.Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy.Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival Genetic heterogeneity of lymphangiogenesis in different mouse strains Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle.Corneal neovascularization: an anti-VEGF therapy review.Spontaneous lymphatic vessel formation and regression in the murine cornea Quantification of corneal neovascularization after ex vivo limbal epithelial stem cell therapy.A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Increased lymphangiogenesis and hemangiogenesis in infant cornea Effect of topical azithromycin on corneal innate immune responses.Photodynamic therapy with verteporfin for corneal neovascularization Safety of bevacizumab on extraocular muscle in a rabbit model.Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.A Drug Delivery System for Administration of Anti-TNF-α Antibody.Evaluation of fungal keratitis using a newly developed computer program, Optscore, for grading digital corneal photographs.Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes.Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.Topical ranibizumab as a treatment of corneal neovascularization Inflammatory corneal neovascularization: etiopathogenesis.Emerging techniques to treat corneal neovascularisation The association between corneal neovascularization and visual acuity: a systematic review.Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Current and Upcoming Therapies for Ocular Surface Chemical Injuries.Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model.Minimally invasive microneedles for ocular drug delivery.Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment.Corneal penetration of topical and subconjunctival bevacizumab.Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.

P2860

Q26823757-B44D7933-D22D-409E-9DE5-A164A83B3C08 Q28083405-58AB4A84-BACD-4FE1-A1F1-5BE67AFCFCB1 Q29999764-802F54DE-8FA3-4A08-B6B5-AAEC4DA40668 Q33519478-515CB1FA-5581-4A90-9AD0-733050473894 Q33774982-B122B5E0-1400-439A-B23C-8C667159744D Q33816513-56CD89D9-DFB9-4B3B-9F1F-83C264F26405 Q33845555-6AF728CD-DBF0-4E57-99F1-35719F24F36E Q33947359-1E64010A-4FEB-4CD5-BFAC-EA9FFDBB452A Q34062422-73E20BED-E2F2-4E5C-AF36-B828E87950F1 Q34088274-868D864F-0FED-478C-8134-FC48DD9C9980 Q34493789-44DC8F53-8531-483E-BD9D-C50F5EA6CD8B Q34596341-0F8535F9-B9B8-448B-90A0-105EF76204C2 Q34641522-CE7924BD-1D07-47B9-82D1-54AA80CAF6ED Q34646670-14C4FFCC-4FA2-44B7-B3C2-A4BA9AD78795 Q34735822-322D7415-C360-4561-9670-EFA6889243BB Q34973743-264B1CCF-DC31-4D35-B834-BEF8962CD982 Q35051497-EABB8F96-5DA0-4433-9DDD-767E01445C7A Q35684022-F1FEB8D0-FDD9-4007-BD7D-12720BBA82F5 Q35964569-E719E76F-EADA-4395-A993-1B1757B4F4F6 Q36128246-7FC0D764-59C3-4EA8-8BDD-5D760F8E0585 Q36571709-1622C2DD-E706-4628-964B-34B944100995 Q36683809-DD740402-FEB3-40E9-B73A-52FBC519CBC3 Q37167446-2BAB9279-28BF-4CB4-873C-6E466D083CA3 Q37218666-E5F3ADB6-E755-4302-9316-ACD3C38B477F Q37425259-B152EBA4-1139-4B68-8DF6-D8DC5B797D0E Q37549985-8B6CECD7-CF03-4210-BA64-71AA0668B053 Q37573788-5D5876AA-2D49-4CC9-9651-52863CC78BAF Q37577521-60B4A2ED-8875-4BCD-B5E0-3A2AFE90F903 Q37940578-7928C480-655F-495E-A349-09D6561F08D0 Q37943247-3B6578A3-C381-4DD7-9AA2-B91DA42B2727 Q37959022-6B4AE2FA-8D89-4AEE-BE5B-2D29B88A71B4 Q38755418-0A4FE79B-8312-44AC-96B5-C1BA739BA34F Q38819339-2066A359-7932-41FF-B04B-82B0B3A6CEBE Q38908590-4F0757C3-A25D-4C9E-BFCB-19C50914EA3E Q38916649-078C7EA7-8946-4092-89D6-182D3911F900 Q38958273-87AAF3ED-1D67-4DE7-AA89-48ACA426B327 Q39589760-94346324-8CBC-43A5-BDB9-9DEADA70DC14 Q39918424-672684B6-26BC-4DD2-93E4-23897EC86E82 Q40018607-40D62D77-9556-4386-8990-199A9D23EF93 Q40032771-E9427E13-1A8F-48BD-AD48-21CD069D1EF9

P2860

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

http://www.wikidata.org/entity/Q37244781

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@en

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@nl

type

label

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@en

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@nl

prefLabel

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@en

Topical bevacizumab in the tre ...... n-label, noncomparative study.

@nl

P1433

Q37244781-D031AAA5-5A2C-419A-AE08-BE4F83E27295

P1476

Q37244781-0AE6D21B-0E8E-4968-A15E-441A3D4AB5D6

P2093

Q37244781-78A1137D-FD1F-428C-A0B4-09DA08043B94

Q37244781-79620B31-2001-4A33-A9F8-4A796976A976

Q37244781-80E05BF1-5FE4-4D88-835B-65932A0C051F

Q37244781-A237B4A2-D068-43E1-A46A-119BA6953FE8

Q37244781-A6EC0BD5-974E-4497-B05F-2ABC84233AE1

Q37244781-CF4403DE-700F-48EA-9533-3C0A95088D6B

Q37244781-F7B834FA-DB2F-4440-8F28-A217DCEAFED3

P2860

Q37244781-169A3F3B-CBF5-4BCA-8677-579F4A74455F

Q37244781-1CCFCF04-E664-4F71-B1C3-F883A697B5A1

Q37244781-2AD02D9B-1A0E-4BE9-8010-5DA9CDF9582D

Q37244781-31316F06-5856-4E5E-9AF3-BEF8862E9951

Q37244781-5318E819-DF3D-4367-9CBA-E0D623F63E17

Q37244781-65769E79-79DB-466E-B96C-2A52A8AE1CA9

Q37244781-66969855-B411-4AAE-ACB7-D1F60C6F91E5

Q37244781-671C8C09-BA54-4495-9BBD-E0AE8F67A1D2

Q37244781-6FCDC0FE-7131-4E1B-8002-3A14AFBD5DD5

Q37244781-7315FD9D-6AEE-46AF-B0CE-60DA30E64DB1

P304

Q37244781-CCB2D488-0BF7-4E69-849E-8896607501C7

P31

Q37244781-5847DD54-09BB-4606-AF12-C4AE8E821BEB

P356

Q37244781-C5485EC2-0F29-49B9-B97D-B84DA76E4A58

P407

Q37244781-9AEF5D68-494C-4E1E-9356-59A4CF8E4DC2

P433

Q37244781-7479FCCD-2765-446A-AF1B-015CC5D88F08

P478

Q37244781-DD490A87-C170-41B5-A26B-6FAF44D45AC9

P50

Q37244781-35616CC5-D992-4964-BF9A-529021BC569B

P577

Q37244781-42D79DB0-748C-4F70-8F64-B3C431A5D76B

P5875

Q37244781-C434E48D-5C6A-4EA6-9171-2A6D42A71FD1

P698

Q37244781-4C417B16-DA9F-435F-ADE5-DC2F739B34A8

P921

Q37244781-0AA3C9E6-1865-4918-BBFD-CD2CA9EF4284

Q37244781-6B4BDE0B-23FA-4B4E-9C23-10CE268D9316

P932

Q37244781-F5D6EE69-D064-4ABA-BCE1-CC73AAA87323

P356

ARCHOPHTHALMOL.2009.18

P1433

JAMA Ophthalmology

P1476

Topical bevacizumab in the tre ...... en-label, noncomparative study

@en

P2093

Deborah Pavan-Langston

http://www.w3.org/2001/XMLSchema#string

Khalid M Al-Arfaj

http://www.w3.org/2001/XMLSchema#string

Mohammad H Dastjerdi

http://www.w3.org/2001/XMLSchema#string

Pedram Hamrah

http://www.w3.org/2001/XMLSchema#string

Reza Dana

http://www.w3.org/2001/XMLSchema#string

Roberto Pineda

http://www.w3.org/2001/XMLSchema#string

Ula V Jurkunas

http://www.w3.org/2001/XMLSchema#string

P2860

Global data on visual impairment in the year 2002

Corneal neovascularization. Pathogenesis and inhibition

Angiogenesis in cancer, vascular, rheumatoid and other disease

Corneal neovascularization.

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

Role of vascular endothelial growth factor in regulation of physiological angiogenesis.

Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.

Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization.

Molecular and biological properties of the vascular endothelial growth factor family of proteins.

P304

381-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHTHALMOL.2009.18

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Nambi Nallasamy

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24276242

http://www.w3.org/2001/XMLSchema#string

P698

19365012

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

2703579

http://www.w3.org/2001/XMLSchema#string